| Autor: |
Malcolm West, Adrienne Kirby, Ralph A. Stewart, Stefan Blankenberg, David Sullivan, Harvey D. White, David Hunt, Ian Marschner, Edward Janus, Leonard Kritharides, Gerald F. Watts, John Simes, Andrew M. Tonkin, Neil Anderson, Ralph Stewart, Harvey White, Paul Nestel, Paul Glasziou, Marian Gandy, Jeannie Joughin, Jennifer Seabrook, Jenny Stephenson, Alison Clague, Stephen MacMahon, Philip Aylward, Malcolm Whiting, John McNeil, Andrew Tonkin, Craig Anderson, Jenny Baker, Elizabeth Barnes, Wendy Hague, Anthony Keech, Li‐Ping Li, Sarah Mulray, Helen Pater, Kristy Robledo, R. John Simes, Paul Magnus, John Shaw, Rory Collins, Andrew Thomson, Phillip Harris, Norman Sharpe, Paul Meier, Philip Barter, John Watson, Lawrence Beilin, Graeme Hankey, Michael Hobbs, Peter Thompson, Gerald Watts, David Colquhoun |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association. 11(5) |
| ISSN: |
2047-9980 |
| Popis: |
Background Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long‐term or is independent of renal function and other important biomarkers. Methods and Results Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long‐Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow‐up, 6 years) and long‐term (median follow‐up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR‐creatinine, then GFR‐creatinine‐cystatin C). Over 6 years, in fully adjusted multivariable time‐to‐event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07–1.74; P =0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19–1.82; P P Conclusions Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all‐cause mortality. Prediction of long‐term mortality was independent of improved estimation of GFR. Registration URL: https://anzctr.org.au ; Unique identifier: ACTRN12616000535471. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text